 |
|
Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid Arthritis
Mary Chester M. Wasko, MD, MSc;
Helen B. Hubert, MPH, PhD;
Vijaya Bharathi Lingala, PhD;
Jennifer R. Elliott, MD;
Michael E. Luggen, MD;
James F. Fries, MD;
Michael M. Ward, MD, MPH
JAMA. 2007;298:187-193.
Context Hydroxychloroquine, a commonly used antirheumatic medication, has hypoglycemic effects and may reduce the risk of diabetes mellitus.
Objective To determine the association between hydroxychloroquine use and the incidence of self-reported diabetes in a cohort of patients with rheumatoid arthritis.
Design, Setting, and Patients A prospective, multicenter observational study of 4905 adults with rheumatoid arthritis (1808 had taken hydroxychloroquine and 3097 had never taken hydroxychloroquine) and no diagnosis or treatment for diabetes in outpatient university-based and community-based rheumatology practices with 21.5 years of follow-up (January 1983 through July 2004).
Main Outcome Measures Diabetes by self-report of diagnosis or hypoglycemic medication use.
Results During the observation period, incident diabetes was reported by 54 patients who had taken hydroxychloroquine and by 171 patients who had never taken hydroxychloroquine, with incidence rates of 5.2 per 1000 patient-years of observation compared with 8.9 per 1000 patient-years of observation, respectively (P < .001). In time-varying multivariable analysis with adjustments for possible confounding factors, the hazard ratio for incident diabetes among patients who had taken hydroxychloroquine was 0.62 (95% confidence interval, 0.42-0.92) compared with those who had not taken hydroxychloroquine. In Poisson regression, the risk of incident diabetes was significantly reduced with increased duration of hydroxychloroquine use (P < .001 for trend); among those taking hydroxychloroquine for more than 4 years (n = 384), the adjusted relative risk of developing diabetes was 0.23 (95% confidence interval, 0.11-0.50; P < .001), compared with those who had not taken hydroxychloroquine.
Conclusion Among patients with rheumatoid arthritis, use of hydroxychloroquine is associated with a reduced risk of diabetes.
Author Affiliations: Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania (Drs Wasko and Elliott); Stanford University Medical Center, Palo Alto, California (Drs Hubert, Lingala, and Fries); Division of Immunology, University of Cincinnati, Cincinnati, Ohio (Dr Luggen); and Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland (Dr Ward).
RELATED LETTER
Risk of Diabetes in Patients With Rheumatoid Arthritis Taking Hydroxychloroquine
Gabriele Di Comite and Carlo M. Rossi
JAMA. 2007;298(20):2368-2369.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hydroxychloroquine: the cornerstone of lupus therapy
Ruiz-Irastorza and Khamashta
Lupus 2008;17:271-273.
Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival
Siso et al.
Lupus 2008;17:281-288.
ABSTRACT
Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA
Cansu and Korkmaz
Rheumatology (Oxford) 2008;47:378-379.
FULL TEXT
Risk of Diabetes in Patients With Rheumatoid Arthritis Taking Hydroxychloroquine
Di Comite and Rossi
JAMA 2007;298:2368-2369.
FULL TEXT
|
